JP2022508953A5 - - Google Patents

Info

Publication number
JP2022508953A5
JP2022508953A5 JP2021547054A JP2021547054A JP2022508953A5 JP 2022508953 A5 JP2022508953 A5 JP 2022508953A5 JP 2021547054 A JP2021547054 A JP 2021547054A JP 2021547054 A JP2021547054 A JP 2021547054A JP 2022508953 A5 JP2022508953 A5 JP 2022508953A5
Authority
JP
Japan
Prior art keywords
alkyl
pharmaceutically acceptable
acceptable salt
compound according
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021547054A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022508953A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/057362 external-priority patent/WO2020086533A1/en
Publication of JP2022508953A publication Critical patent/JP2022508953A/ja
Publication of JP2022508953A5 publication Critical patent/JP2022508953A5/ja
Pending legal-status Critical Current

Links

JP2021547054A 2018-10-22 2019-10-22 Hbvの処置のための5員のヘテロアリールカルボキサミド化合物 Pending JP2022508953A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862748906P 2018-10-22 2018-10-22
US62/748,906 2018-10-22
US201962858790P 2019-06-07 2019-06-07
US62/858,790 2019-06-07
PCT/US2019/057362 WO2020086533A1 (en) 2018-10-22 2019-10-22 5-membered heteroaryl carboxamide compounds for treatment of hbv

Publications (2)

Publication Number Publication Date
JP2022508953A JP2022508953A (ja) 2022-01-19
JP2022508953A5 true JP2022508953A5 (cg-RX-API-DMAC10.html) 2023-06-22

Family

ID=68610300

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021547054A Pending JP2022508953A (ja) 2018-10-22 2019-10-22 Hbvの処置のための5員のヘテロアリールカルボキサミド化合物

Country Status (15)

Country Link
US (2) US11560370B1 (cg-RX-API-DMAC10.html)
EP (1) EP3870296A1 (cg-RX-API-DMAC10.html)
JP (1) JP2022508953A (cg-RX-API-DMAC10.html)
KR (1) KR20210095143A (cg-RX-API-DMAC10.html)
CN (1) CN113195055A (cg-RX-API-DMAC10.html)
AU (1) AU2019364352A1 (cg-RX-API-DMAC10.html)
BR (1) BR112021007602A2 (cg-RX-API-DMAC10.html)
CA (1) CA3117449A1 (cg-RX-API-DMAC10.html)
IL (1) IL282433A (cg-RX-API-DMAC10.html)
MA (1) MA53983A (cg-RX-API-DMAC10.html)
MX (1) MX2021004580A (cg-RX-API-DMAC10.html)
PH (1) PH12021550887A1 (cg-RX-API-DMAC10.html)
SG (1) SG11202104086PA (cg-RX-API-DMAC10.html)
TW (1) TW202028190A (cg-RX-API-DMAC10.html)
WO (1) WO2020086533A1 (cg-RX-API-DMAC10.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111205264A (zh) * 2020-02-25 2020-05-29 成都睿智化学研究有限公司 一种合成同位羟基和甲磺酰甲基化合物的新方法
US20230295096A1 (en) * 2020-04-22 2023-09-21 Assembly Biosciences, Inc. Pyrazole carboxamide compounds for treatment of hbv
AU2021261307B2 (en) * 2020-04-22 2026-06-18 Assembly Biosciences, Inc. 5-membered heteroaryl carboxamide compounds for treatment of HBV
JP2023551474A (ja) * 2020-11-25 2023-12-08 エフ. ホフマン-ラ ロシュ アーゲー B型肝炎ウイルス感染症の処置および予防のための芳香族架橋環アミド誘導体
JP2024541124A (ja) * 2021-10-20 2024-11-06 アセンブリー・バイオサイエンシーズ・インコーポレイテッド 新規結晶形態
WO2023069547A1 (en) * 2021-10-20 2023-04-27 Assembly Biosciences, Inc. 5-membered heteroaryl carboxamide compounds for treatment of hbv
KR20240089748A (ko) * 2021-10-20 2024-06-20 어셈블리 바이오사이언시스, 인크. 방법
WO2023105481A1 (en) * 2021-12-10 2023-06-15 Assembly Biosciences, Inc. Pharmaceutical compositions for the treatment of hbv
WO2024173196A1 (en) * 2023-02-17 2024-08-22 Merck Sharp & Dohme Llc Plasma kallikrein inhibitors
KR102827002B1 (ko) * 2023-06-28 2025-06-30 국립순천대학교산학협력단 신규한 마리노바자난 화합물 및 이를 포함하는 암 전이 및 침윤 억제, 또는 암 치료용 조성물
WO2025029961A1 (en) * 2023-07-31 2025-02-06 Makscientific, Llc Pharmaceutical compositions, and preparation and methods of use thereof
WO2025087274A1 (zh) 2023-10-27 2025-05-01 浙江海正药业股份有限公司 氮杂双环类衍生物及其制备方法和用途
CN117603089A (zh) * 2023-11-29 2024-02-27 南通瑞合达医药科技有限公司 一种环戊腈的合成方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ530782A (en) * 2001-08-06 2005-11-25 Pharmacia Italia S Aminoisoxazole derivatives active as kinase inhibitors
GB0228417D0 (en) * 2002-12-05 2003-01-08 Cancer Rec Tech Ltd Pyrazole compounds
WO2008130584A1 (en) 2007-04-20 2008-10-30 Schering Corporation Pyrimidinone derivatives and methods of use thereof
CN105853415A (zh) * 2009-05-12 2016-08-17 罗马克实验室有限公司 卤代烷基杂芳基苯甲酰胺化合物
WO2013006394A1 (en) 2011-07-01 2013-01-10 Institute For Hepatitis And Virus Research Sulfamoylbenzamide derivatives as antiviral agents against hbv infection
US9968650B2 (en) 2011-07-13 2018-05-15 Indiana University Research And Technology Corporation Modified viral structural protein with antiviral activity
AR089671A1 (es) 2012-01-06 2014-09-10 Janssen R & D Ireland 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
NZ704758A (en) 2012-08-28 2018-06-29 Janssen Sciences Ireland Uc Fused bicyclic sulfamoyl derivatives and the use thereof as medicaments for the treatment of hepatitis b
CA2881057C (en) 2012-08-28 2020-10-27 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
CA2881322A1 (en) 2012-09-10 2014-03-13 F. Hoffmann-La Roche Ag 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
HK1215030A1 (zh) 2012-11-09 2016-08-12 Indiana University Research And Technology Corporation 用於hbv組裝效應劑的替代用途
CN104918612B (zh) 2012-12-06 2019-10-25 巴鲁克斯布隆伯格研究所 作为抗hbv感染的抗病毒剂的官能化苯甲酰胺衍生物
HK1217649A1 (zh) 2012-12-27 2017-01-20 德雷克塞尔大学 針對hbv感染的新型抗病毒劑
JP6466348B2 (ja) 2013-02-28 2019-02-06 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー スルファモイル−アリールアミドおよびb型肝炎を処置するための医薬品としてのその使用
HUE033542T2 (en) 2013-04-03 2017-12-28 Janssen Sciences Ireland Uc Their use as medicaments for the treatment of N-phenylcarboxamide derivatives and hepatitis B
TW202126620A (zh) 2013-05-17 2021-07-16 愛爾蘭商健生科學愛爾蘭無限公司 胺磺醯基吡咯醯胺衍生物及其作為用於治療b型肝炎藥物的用途
PE20151951A1 (es) 2013-05-17 2015-12-26 Hoffmann La Roche Heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b
HUE040446T2 (hu) 2013-05-17 2019-03-28 Janssen Sciences Ireland Uc Szulfamoiltiofenamid-származékok és gyógyszerként történõ alkalmazásuk hepatitis B kezelésére
WO2015011281A1 (en) 2013-07-25 2015-01-29 Janssen R&D Ireland Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
CA2928003A1 (en) * 2013-11-14 2015-05-21 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis b infections
PL3102572T3 (pl) 2014-02-06 2019-04-30 Janssen Sciences Ireland Uc Pochodne sulfamoilopirolamidu i ich zastosowanie jako leki do leczenia wirusowego zapalenia wątroby typu B
EP3271019A1 (en) * 2015-03-19 2018-01-24 Novira Therapeutics Inc. Azocane and azonane derivatives and methods of treating hepatitis b infections
CN105503730B (zh) * 2015-12-25 2018-06-22 山东大学 吡唑类衍生物及其制备方法与应用
UY37581A (es) * 2017-02-02 2018-08-31 Gilead Sciences Inc Compuestos para el tratamiento de la infección por virus de la hepatitis b
CN108250112B (zh) * 2018-01-30 2019-08-27 西北大学 一种1-烷基-1-芳硫基-2-(1h)-萘酮衍生物及其制备方法

Similar Documents

Publication Publication Date Title
JP2023523241A5 (cg-RX-API-DMAC10.html)
RU2007116119A (ru) Производные циклоспорина, замещенные 3-эфиром и 3-тиоэфиром, для лечения и профилактики инфекционного гепатита с
JP2005532389A5 (cg-RX-API-DMAC10.html)
JP2010504347A5 (cg-RX-API-DMAC10.html)
JP2010504346A5 (cg-RX-API-DMAC10.html)
JP2023502441A5 (cg-RX-API-DMAC10.html)
JP2004516314A5 (cg-RX-API-DMAC10.html)
JP2008510771A5 (cg-RX-API-DMAC10.html)
RU2007123235A (ru) Противоопухолевые соединения
JP2008514732A5 (cg-RX-API-DMAC10.html)
JP2018021051A5 (cg-RX-API-DMAC10.html)
JP2009504763A5 (cg-RX-API-DMAC10.html)
JP2007511527A5 (cg-RX-API-DMAC10.html)
JP2012505836A5 (cg-RX-API-DMAC10.html)
JP2014500265A5 (cg-RX-API-DMAC10.html)
JP2005538057A5 (cg-RX-API-DMAC10.html)
JP2008503515A5 (cg-RX-API-DMAC10.html)
JP2003501474A5 (cg-RX-API-DMAC10.html)
RU2005107314A (ru) Пиримидопроизводные, характеризующиеся антипролиферативной активностью
JP2014531449A5 (cg-RX-API-DMAC10.html)
JP2007529421A5 (cg-RX-API-DMAC10.html)
JP2017523169A5 (cg-RX-API-DMAC10.html)
RU2013130256A (ru) Новые циклоспориновые производные для лечения и предупреждения вирусных инфекций
JP2015504081A5 (cg-RX-API-DMAC10.html)
JP2019512465A5 (cg-RX-API-DMAC10.html)